Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive

Ann Rheum Dis. 2020 Nov;79(11):1516-1517. doi: 10.1136/annrheumdis-2020-217725. Epub 2020 May 28.
No abstract available

Keywords: anti-citrullinated protein antibodies; arthritis, rheumatoid; methotrexate; rheumatoid factor; tumor necrosis factor inhibitors.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / therapeutic use
  • Anti-Citrullinated Protein Antibodies / blood
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / drug therapy*
  • Etanercept / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Methotrexate / therapeutic use*
  • Retrospective Studies
  • Rheumatoid Factor / blood
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

  • Anti-Citrullinated Protein Antibodies
  • Immunosuppressive Agents
  • Tumor Necrosis Factor Inhibitors
  • Rheumatoid Factor
  • Adalimumab
  • Etanercept
  • Methotrexate